CagriSema REDEFINE 1 shows 22.7% mean weight loss, below Novo's 25% expectation

Novo Nordisk/CagriSema

In REDEFINE 1, CagriSema (cagrilintide plus semaglutide) gave 22.7% mean weight loss at 68 weeks if all patients adhered to treatment (20.4% vs 3.0% on placebo counting everyone enrolled). Only 57.3% of patients reached the highest dose under the flexible dosing protocol, falling short of Novo's earlier 25% target.

• Weight loss (all-adherence estimand): 22.7% vs. 3.0% placebo at 68 weeks.
• Weight loss (all-participant estimand): 20.4% vs. 3.0% placebo.
• Dose achievement: only 57.3% reached highest CagriSema dose.
• Strength: 40.4% achieved ≥25% weight loss; 97.6% achieved ≥5% loss.